Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Gynecologic 8CNS 8Sarcoma 6Gastrointestinal 6Genitourinary 5Thoracic 4Myeloid 3Breast 3Other neoplasm 2Endocrine 2Classical hematology 2Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Methylation × Dermatologic × Clear all
NCT01209299 2017-05-17

Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

Eastern Cooperative Oncology Group

Completed
80 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡